12:00 AM
 | 
Sep 14, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Finerenone: Phase IIb data

The double-blind, placebo-controlled, international Phase IIb ARTS-HF trial in about 1,058 patients who presented to an emergency department with worsening CHF with reduced ejection fraction and Type II diabetes and/or chronic kidney disease (CKD) showed that the proportion of patients with a >=30% reduction in NT-proBNP levels from baseline to day 90, the primary endpoint,...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >